Litigation Details for ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited (D. Del. 2020)
✉ Email this page to a colleague
ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited (D. Del. 2020)
| Docket | ⤷ Subscribe | Date Filed | 2020-07-24 |
| Court | District Court, D. Delaware | Date Terminated | 2024-05-07 |
| Cause | 35:271 Patent Infringement | Assigned To | Gregory B. Williams |
| Jury Demand | None | Referred To | |
| Parties | TEVA PHARMACEUTICALS USA, INC. | ||
| Patents | 10,028,944; 10,188,632; 10,449,185; 10,517,860; 6,756,393; 6,815,458; 7,115,634; 7,601,740; 7,659,285; 7,732,615; 7,741,356; 7,786,158; 7,863,296; 7,923,564; 8,344,011; 8,618,130; 8,691,860; 8,921,393; 9,115,091; 9,296,694; 9,364,489; 9,566,271; 9,675,587; 9,789,125 | ||
| Attorneys | David A. Bilson | ||
| Firms | Saul Ewing Arnstein & Lehr LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited
The small molecule drugs covered by the patents cited in this case are ⤷ Subscribe and ⤷ Subscribe .
Biologic Drugs cited in ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited
The biologic drug covered by the patents cited in this case is ⤷ Subscribe .
Details for ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2020-07-24 | 1 | Complaint | States Patent Nos. 7,601,740 (“the ’740 patent”), 7,732,615 (“the ’615 patent”), 10,449,185 (“the ’185…’185 patent”), and 10,646,480 (“the ’480 patent”) (collectively “the patents-in-suit”). This action arises… of the ’740 patent is attached as Exhibit A. 26. ACADIA owns the ’740 patent. 27.…of the ’615 patent is attached as Exhibit B. 28. ACADIA owns the ’615 patent. 29.… of the ’185 patent is attached as Exhibit C. 30. ACADIA owns the ’185 patent. | External link to document |
| 2021-08-10 | 117 | Stipulation-General (See Motion List for Stipulation to Extend Time) | 16 of U.S. Patent No. 10,646,480, Claim 3 of U.S. Patent No. 10,449,185, and Claims…8 of U.S. Patent No. 10,646,480 and Claim 1 of U.S. Patent No. 10,449,185; and … of the ’480 patent, the ’185 patent, and the ’891 patent with respect to … lubricant” appearing in Claims 1 and 6 of U.S. Patent No. 10,849,891; • “a D90 particle…Claims 7 and 11 of U.S. Patent No. 10,849,891; 38842524.2 Case 1:20-cv-00985-RGA Document | External link to document |
| 2020-09-01 | 12 | Patent/Trademark Report to Commissioner of Patents | ,923,564 ;8,618,130 ;8,921,393 ;9,566,271 ;10,028,944 . (Dorsney, Kenneth) (Entered: 09/01/2020) 1… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,659,285 ;7,923,564…July 2020 7 May 2024 1:20-cv-00985 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
